HDHalston Deal

Halston Deal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Halston Deal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microfluidic Platform for Multiparametric Profiling of Fibrin Permeability, Fibrinolysis, and Cell Invasion

    by Halston Deal, Elizabeth M. Byrnes, Sanika Pandit, Halle J. Cantor, Muskan Aslam, Stacy Ban, Megan Palmisano, Rosemary Bayless, Ashley C. Brown, Michael Daniele

    Fibrin's dual role, as a transient scaffold guiding wound repair and as a pathogenic matrix in thrombosis, demands tools that can profile how its transport properties, degradability, and cellular remodeling evolve under different biochemical, engineering, and ultimately patient‐specific conditions. Here, we introduce a single‐channel, H‐junction microfluidic platform that enables multiplexed, real‐time quantification of fibrin permeability, fibrinolysis kinetics, fibroblast invasion, and clot extension within the same hydrogel. Using time‐lapse confocal microscopy, the assay captured solute permeability coefficients from 1.98 × 10 −5 to 1.67 × 10 −4 cm 2 ∙s −1 , fibrinolysis half‐times down to 12 min, and cell migration, with quantitative analysis performed in a ∼3 µL gel volume. Systematic variation of fibrinogen concentration (1.5–10 mg∙mL −1 ) and FXIII crosslink density reveals a 3.7‐fold span in permeability, a ninefold shift in lysis rate, and up to 64% suppression of fibroblast penetration, as fibrinogen concentration increases. Because the chip uses standard soft‐lithography and conventional microscopy tools, it can be integrated into existing microphysiological systems or deployed as a high‐throughput screening tool for anticoagulants, pro‐healing therapies, and patient‐specific risk assessment. This versatile platform thus bridges mechanistic fibrin research and translational biomaterials design, opening new avenues for precision thrombosis modelling and regenerative medicine.

  • Open Access

    Molecular Engineering of Cyclic Azobenzene‐Peptide Hybrid Ligands for the Purification of Human Blood Factor VIII via Photo‐Affinity Chromatography

    by Raphael Prodromou, Brandyn David Moore, Wenning Chu, Halston Deal, Adriana San Miguel, Ashley Carson Brown, Michael Angelo‐Anthony Daniele, Vladimir Aleksandrovich Pozdin, Stefano Menegatti

    The use of benign stimuli to control the binding and release of labile biologics for their isolation from complex feedstocks is a key goal of modern biopharmaceutical technology. This study introduces cyclic azobenzene‐peptide (CAP) ligands for the rapid and discrete photo‐responsive capture and release of blood coagulation factor VIII (FVIII). A predictive method—based on amino acid sequence and molecular architecture of CAPs—is developed to correlate the conformation of cis/trans‐CAP photo‐isomers to FVIII binding and release. Combined in silico ‐ in vitro analysis of FVIII:peptide interactions guide the design of a rational approach to optimize isomerization kinetics and biorecognition of CAPs. A photoaffinity adsorbent, prepared by conjugating selected CAP G‐cycloAZOB[Lys‐YYKHLYN‐Lys]‐G on translucent chromatographic beads, features high binding capacity (>6 mg of FVIII per mL of resin) and rapid photo‐isomerization kinetics (τ < 30 s) when exposed to 420–450 nm light at the intensity of 0.1 W cm−2. The adsorbent purifies FVIII from a recombinant harvest using a single mobile phase, affording high product yield (>90%), purity (>95%), and blood clotting activity. The CAPs introduced in this report demonstrate a novel route integrating gentle operational conditions in a rapid and efficient bioprocess for the purification of life‐saving biotherapeutics.